In a phase 3 study, the interleukin (IL)-17 blocker ixekizumab showed a similar efficacy in paediatric patients with moderate-to-severe psoriasis as previously demonstrated in adult patients .
Although the first symptoms of psoriasis symptoms present during childhood in one-third of patients, there is still an unmet need for effective and safe therapies for children and adolescents with moderate-to-severe plaque psoriasis. This was the rationale for the IXORA-PEDS study, presented at the EADV Congress by Dr Kim Papp (Probity Medical Research, Canada).
The study evaluated the efficacy and safety of ixekizumab in 203 psoriasis patients between 6 to 18 years old. In a double-blind induction period participants received ixekizumab (n=115; 40 mg, 80 mg, or 160 mg depending on body weight), etanercept (n=30; 0.8 mg/kg), or placebo (n=58) for 12 weeks. At week 12, all participants switched to...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Small molecules: interesting novel treatment options in AD Next Article
Pivotal Phase 3 Trial in Cold Agglutinin Disease »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.